Tatva Chintan Pharma Chem Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹217 Cr +75% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
TC

Tatva Chintan Pharma Chem Ltd

Q1 FY26Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹117Cr
+11.4% YoY
+8.3% QoQ
Net profit
₹7Cr
+40% YoY
+600% QoQ
Margin
15%
+3 pp YoY
+7 pp QoQ
Price₹1,616
Market cap₹4.0K Cr
P/E76.8

The short version

Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025. FY '26 revenue growth guidance: ~25% compared to FY '25.

From Tatva Chintan Pharma Chem Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025.
  • SDA (Structure Directing Agents) segment revenues anticipated to grow with better margin realization, supported by near full plant capacity utilization.
  • Electrolyte salts segment projected to contribute roughly 10% to the top line by FY 26-27, with significant volume growth (~200% growth mentioned).
  • PASC (Pharma & Agro and Specialty Chemicals) segment gaining traction, expected to be a significant revenue contributor in FY 26 and beyond.
  • Semiconductor segment starting commercialization with full-scale expected by 2029, showing promising long-term potential.
  • Addressable market in SDA estimated at around 20% currently, with further volume increases planned.

2 more points from Tatva Chintan Pharma Chem Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY '26 capex plan is about INR 110 crores.
  • New greenfield facility planned at Jolva to support additional capex for agro intermediate production.
  • Minor capex under consideration for modifications and automation in semiconductor chemical production to move from pilot to plant scale.
  • Additional capex expected for expanding electrolyte segment capacity, especially for supercapacitor and hybrid vehicle batteries requiring ultra-dry/ultra-pure handling and closed systems.
  • Potential further expansions and automation anticipated for semiconductor and electrolyte businesses as volumes grow.

2 more points from Tatva Chintan Pharma Chem Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company has high confidence in order execution with clear visibility of orders till at least December 2025.
  • Most of the orders are already on hand, ensuring no uncertainty regarding near-term order fulfillment.
  • Bulk orders in the PASC (Phase Transfer Catalyst) segment are set to commence supplies from early 2026.
  • New orders and approvals in the electrolyte segment, including batteries for hybrid vehicles, indicate growing demand and commercial traction.
  • There is clear visibility of significant orders ramping up in Q2 and Q3 of FY '26.

2 more points from Tatva Chintan Pharma Chem Ltd's call on order book

Create a free account to keep reading this call

Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Tatva Chintan Pharma Chem Ltd Q1 FY26 results — key figures

Tatva Chintan Pharma Chem Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue117105+11.4%108+8.3%
Operating profit (EBITDA)1713+30.8%9+88.9%
Operating margin15%12%+3 pp8%+7 pp
Profit before tax97+28.6%2+350%
Net profit (PAT)75+40%1+600%
EPS (₹)2.842.23+27.4%0.44+545.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Balaji Amines (Q1 FY26)

    Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…

  • Linde India (Q1 FY26)

    Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…

  • Vidhi Specialty (Q1 FY26)

    87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • Chemcon Speciality Chemicals (Q1 FY26)

    Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Tatva Chintan Pharma Chem Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Tatva Chintan Pharma Chem Ltd Q1 FY26 results?

Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025. FY '26 revenue growth guidance: ~25% compared to FY '25.

What is Tatva Chintan Pharma Chem Ltd share price analysis?

Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.

Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?

FY '26 capex plan is about INR 110 crores.

Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.